Drugs · acquisition-cost intelligence
Afinitor
everolimus· ingredient everolimusMammalian target of rapamycin (mTOR) kinase inhibitors· EVEROLIMUS 10 mg/1; EVEROLIMUS 2.5 mg/1; EVEROLIMUS 2 mg/1; EVEROLIMUS 3 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$26.32
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-06-03
Same-ingredient options by acquisition cost
Other everolimus products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Everolimus | $3.60 | −$22.72 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 5
Prior auth 99% · Step therapy 0% · Quantity limit 90% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.